Search results for "Neutropenia"

showing 9 items of 219 documents

Skelettveränderungen bei Frühgeborenen mit Kupfermangel

1991

We describe 5 preterm infants (25th to 30th week of gestation) suffering from alimentary copper deficiency. The diagnosis was confirmed by low serum copper and caeruloplasmin concentrations. Characteristic clinical findings were repeated apnoeic attacks, hypopigmentation of skin and hair, anaemia, neutropenia and leucopenia refractory to other therapy, as well as increasing serum alkaline phosphatase activity in the first month of life. Starting in the 3rd to 12th week of life the radiographic findings were general skeletal osteoporosis and retardation, metaphyseal radiodense lines, irregular metaphyses, cupping and spurring of the metaphyses, followed by multiple fractures and subperiostea…

medicine.medical_specialtybusiness.industryOsteoporosisNeutropeniamedicine.diseaseSurgeryRefractorymedicineGestationRadiology Nuclear Medicine and imagingApnoeic attacksmedicine.symptomMultiple fracturesbusinessCopper deficiencyHypopigmentationRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Liposomal Amphotericin B for Fever and Neutropenia

1999

medicine.medical_specialtybusiness.industrymedicineLiposomal amphotericinGeneral MedicineNeutropeniaIntensive care medicinebusinessmedicine.diseaseNew England Journal of Medicine
researchProduct

Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective …

2018

Abstract Background: Triplet-based lenalidomide plus dexamethasone (Rd) combinations have become the new standard of care for early relapse and refractory multiple myeloma (RRMM). Carfilzomib is a novel selective proteasome inhibitor (PI) with high efficacy in RRMM. The ASPIRE phase 3 trial showed the superiority of carfilzomib-based triplet (KRd compared to Rd), leading to approval of K for RRMM. However, little is known about safety and efficacy of KRd outside a clinical trial context. Experimental design and aims: In 11 Sicilian Centers belonging to the Sicilian Myeloma Network, from November 2016, when KRd regimen was approved in Italy, to June 2018, 103 consecutive RRMM patients (previ…

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiescomplete remissionImmunologylenalidomideadverse eventContext (language use)dexamethasoneBiochemistrychemistry.chemical_compoundMedian follow-upInternal medicinemedicinecarfilzomib dexamethasone lenalidomide multiple myeloma toxic effect adverse event bortezomib complete remission erythropoietin febrile neutropeniaMultiple myelomaLenalidomidetoxic effectcarfilzomibbusiness.industryCumulative dosebortezomibCell BiologyHematologymedicine.diseaseCarfilzomibmultiple myelomaRegimenfebrile neutropeniachemistryerythropoietinbusinessFebrile neutropeniamedicine.drug
researchProduct

Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Societ…

2005

Patients undergoing allogeneic stem cell transplantation are at high risk for infection with a variety of pathogens during different phases of the procedure. Bacteria and fungi predominate the first phase until engraftment. During the second phase, from engraftment to about day 100, major infectious problems are caused by fungi and cytomegalovirus. Both pathogens remain important under continued immunosuppression, however, in the late post-transplantation period infections with encapsulated bacteria may become a problem. In this review the Infectious Diseases Working Party of the DGHO gives recommendations for prophylaxis of infections under allogeneic stem cell transplantation with drugs a…

medicine.medical_specialtymedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationNeutropenia03 medical and health sciences0302 clinical medicineAnti-Infective AgentsmedicineHumansTransplantation HomologousInfection controlAntibiotic prophylaxisIntensive care medicineBone Marrow TransplantationInfection Controlbusiness.industryImmunosuppressionHematologyAntibiotic ProphylaxisAntimicrobialmedicine.disease3. Good healthTransplantationOncology030220 oncology & carcinogenesisImmunologyPreventive Medicinebusiness030215 immunologyAnnals of Oncology
researchProduct

Polypeptides controlling hematopoietic blood cell development and activation

1989

Colony-stimulating factors (CSFs) have entered the clinical arena. Several investigators have explored, in first clinical phase I studies, different routes of administration to define the optimum biological dose, maximum tolerated dose, toxicity, and pharmacokinetics of these reagents. It has been demonstrated that recombinant human (rh) granulocyte-macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF) can be safely administered over a broad dose range to increase number of circulating granulocytes in man. More recently, GM-CSF and G-CSF have been involved in phase Ib/II studies to assess the granulopoietic responses of patients with granulocytopenia due to various underlying disease states i…

medicine.medical_specialtymedicine.medical_treatmentGranulocyteCyclic neutropeniaColony-Stimulating FactorsBone MarrowInternal medicinemedicineHumansAplastic anemiaChemotherapyHematologybusiness.industryHematologyGeneral MedicineHematopoietic Stem Cellsmedicine.diseaseHematopoiesisGranulocyte colony-stimulating factorHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureImmunologyDrug EvaluationPeptidesbusinessmedicine.drugBlut
researchProduct

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the G…

2018

Abstract Introduction Thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Underlying mechanisms are poorly known and usually multifactorial. Its treatment is not well defined, mostly based in platelet transfusion. Thus, is important to identify new strategies to manage this important post-SCT complication. Romiplostim and Eltrombopag are currently available thrombopoietin receptor agonists (TPO-RAs) that stimulate platelet production. Some studies with very small number of cases have reported their potential efficacy in the allo-SCT setting. For this reason, the aim of our study is to analyze the efficacy and safety of TPO-RAs for s…

medicine.medical_specialtymedicine.medical_treatmentImmunologyEltrombopagHematopoietic stem cell transplantationNeutropeniaBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinePlateletRomiplostimbusiness.industryCell BiologyHematologymedicine.diseaseTransplantationPlatelet transfusionGraft-versus-host diseasechemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drugBlood
researchProduct

Novel Translational Read-through–Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome

2022

Shwachman-Diamond syndrome (SDS) is one of the most commonly inherited bone marrow failure syndromes (IBMFS). In SDS, bone marrow is hypocellular, with marked neutropenia. Moreover, SDS patients have a high risk of developing myelodysplastic syndrome (MDS), which in turn increases the risk of acute myeloid leukemia (AML) from an early age. Most SDS patients are heterozygous for the c.183-184TA>CT (K62X) SBDS nonsense mutation. Fortunately, a plethora of translational read-through inducing drugs (TRIDs) have been developed and tested for several rare inherited diseases due to nonsense mutations so far. The authors previously demonstrated that ataluren (PTC124) can restore full-length SBDS…

neutropeniaMedicine (miscellaneous)atalurenbone marrow failure syndromes; ataluren; neutropeniabone marrow failure syndromesShwachman-Diamond SyndromeGeneral Biochemistry Genetics and Molecular BiologyBiomedicines
researchProduct

The Use of Lenograstim in the prevention of chemotherapy induced neutropenia in patiets with soft tissue sarcoma (STS)

2008

sarcoma chemotherapy neutropenia
researchProduct

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of …

2006

Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They primarily concern clinical entities associated with the reactivation of herpes viruses, such as varicella zoster virus (VZV) and cytomegalovirus (CMV). Respiratory tract infections caused by influenza, parainfluenza or respiratory syncytial virus (RSV) are less common. Since reactivation of latent infections has major clinical impact, antiviral prophylaxis is an attractive approach for patients expecting immunosuppression. The main risk factor for clinically relevant reactivation is profound disruption of cellular immune response. Du…

virusesmedicine.medical_treatmentCongenital cytomegalovirus infectionAntineoplastic AgentsNeutropeniamedicine.disease_causeAntiviral AgentsVirusHerpesviridae03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansRespiratory tract infectionsbusiness.industryVaricella zoster virusvirus diseasesImmunosuppressionHematologymedicine.disease3. Good healthOncologyVirus Diseases030220 oncology & carcinogenesisImmunologyAlemtuzumabbusinessImmunosuppressive Agents030215 immunologymedicine.drugStem Cell TransplantationAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct